St. Louis-based Express Scripts, the nation’s largest pharmacy benefit manager, does not disclose the names of its board members, or any possible conflicts of interest they may have, according to the report. The company’s opaque system is designed to protect experts from the “tremendous” influence of lobbyists, Express Scripts executives told the St. Louis Dispatch, but critics argue the process should be more transparent, especially since such transparency is enforced in other areas of the healthcare industry.
“All of us are subject to reporting on what money we receive. These folks should do the same,” said Adrian Di Bisceglie, MD, co-director of St. Louis University Liver Center, according to the report.
Express Scripts, which provides prescription medications to roughly 85 million Americans each year, negotiates the cost of prescription drugs directly with pharmaceutical companies. The company’s national preferred formulary, or its list of covered drugs, acts as a tool to stunt the rising costs of prescription drugs; the threat of being excluded pressures pharmaceutical companies to lower their prices, according to the report.
Earlier this month, Express Scripts revealed a list of 85 drugs it plans to exclude from insurance coverage in 2017.
More articles on supply chain:
Lethal drug poses new threat to the opioid epidemic
Study: Drug cost predictions overestimate actual healthcare spending
Medline, Community Health Ventures enter group purchasing partnership
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.